Receipt date: 10/14/2008 Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

09211297 - GAU: 1644 PTO/SB/08a (08-08)

Approved for use through 09/30/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

09211297 **Application Number** Filing Date 1998-12-14 INFORMATION DISCLOSURE First Named Inventor Boyle, William J. STATEMENT BY APPLICANT Art Unit 1644 (Not for submission under 37 CFR 1.99) **Examiner Name** Szperka, Michael E. Attorney Docket Number A-451M IDS#2-101408

U.S.PATENTS								Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document				Lines where ges or Relev	
	1										
If you wis	h to a	⊥ dd additional U.S. Pater	⊥ nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1										
If you wis	h to a	⊥ dd additional U.S. Publi	⊥ shed Ap	plication	citation	ı n information p	please click the Add	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document	v F	vhere Rel	or Relevant	T5
/MS/	1	9626217	WO		A1	1996-08-29	Goto et al. (English Equivalent EP 0 81 A1)				
/MS/	2	9700318	wo		A1	1997-01-03	Roodman				
/MS/	3	9807840	wo		A1	1998-02-26	Nakagawa et al.				

Receipt date: 10/14/2008	Application Number		09211297 092	11297 - GAU: 1644	
	Filing Date		1998-12-14		
INFORMATION DISCLOSURE	First Named Inventor	Boyle	, William J.		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1644		
(Not for submission under or of K 1.55)	Examiner Name	Szpei	rka, Michael E.		
	Attorney Docket Numb	er	A-451M IDS#2-10140	08	
			•		

/MS/	4	9846644	WO	A1	1998-10-22	Yamaguchi et al.		
000000000000000000000000000000000000000	5	9846751	WO	A1	1998-10-22	Boyle		
000000000000000000000000000000000000000	6	9849305	WO	A1	1998-11-05	Boyle et al.		
000000000000000000000000000000000000000	7	0874045	EP	A1	1998-10-28	Nakagawa et al.		
сисорососиольский видентательного с	8	0117543	wo	A2	2001-03-15	Dunstan		
иморососфиями в постава и пост	9	0117543	WO	A3	2001-03-15	Dunstan		
	10	0118203	WO	A1	2001-03-15	Dunstan et al.		
000000000000000000000000000000000000000	11	0216551	WO	A2	2002-02-28	Choi et al.		
000000000000000000000000000000000000000	12	0216551	WO	A3	2002-02-28	Choi et al.		
/MS/	13	03002713	WO	A2	2003-01-09	Boyle et al.		
If you wish to add additional Foreign Patent Document citation information please click the Add button NON-PATENT LITERATURE DOCUMENTS						Add Remove		

Receipt date: 10/14/2008

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

				~~~	~~~	~		
Application Number	₀₉₂₁₁₂₉₇ 09211297 - GAU						164	
Filing Date	1998-12-14							
First Named Inventor Boyle		, William J.						
Art Unit	1644							
Examiner Name	ka, Michael	E.						
Attorney Docket Numb	A-451M	IDS#2-	101408					

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T⁵
/MS/	1	O'Brien, E. A. et al., "Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria", Biochem. Biophys. Res. Commun., 274: 281-290 (2000)	
900000000000000000000000000000000000000	2	Oyajobi et al., "Therapeutic efficacy of a soluble receptor activator of nuclear factor kappa-B-igG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hyperclacemia of malignancy", Cancer Res., 61: 2572-2578 (March 15, 2001)	
200000000000000000000000000000000000000	3	Peterson et al., "AMG162, A fully human monoclonal antibody against receptor activator of NF-Kappa B ligand (RANKL), rapidly and profoundly suppresses bone resorption in cynomolgus monkey", Internatl. Bone and Mineral Society-Japan Bone and Mineral Society, 2003, Poster Session 2 "Osteoclasts", Osaka, Japan (June 6, 2003)	
000000000000000000000000000000000000000	4	Reddi, A. H., "Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state", Cell, 89: 151-161 (1997)	
000000000000000000000000000000000000000	5	Reiger et al., Glossary of Genetics and Cytogenetics, p. 17, Springer-Verlag Berlin Heidlberg, New York (1976)	
***************************************	6	Suda, T. et al., "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr. Rev., 20: 345-357 (1999)	
0,000,000,000,000,000	7	Takada et al., "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells", Bone and Mineral, 17: 347-359 (1992)	
000000000000000000000000000000000000000	8	Takeyama, S. et al., "Low calcium environment effects osteoprotegerin ligand/osteoclast differentiation factor", Biochim. Biophys. Res. Commun., 276: 524-529 (2000)	
12,000 constant	9	Teng, Y. A. et al., "Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection", J. Clin. Invest., 106: 749-752 (2000)	
/MS/	10	Tsuda et al., "Isolation of a novel cutokine from human fibroblasts that specifically inhibits osteoclastogenesis", Biochemical and Biophysical Research Communications, 234(1): 137-142 (1997)	

EFS Web 2.1.5 /Michael Szperka/ 01/05/2009

, ,	. , .	10446000			2.24	>			
Receipt date: 10/14/2008			Application Number		₀₉₂₁₁₂₉₇ 09211297 - GAU: 1644				
			Filing Date		1998-12-14				
		TION DISCLOSURE	First Named Inventor Boyle, William J.						
		NT BY APPLICANT nission under 37 CFR 1.99)	Art Unit		1644				
(11011)	Jubii	inssion under or or it isog	Examiner Name Szperka, Michael E.						
			Attorney Docket Numb	Attorney Docket Number A-451M IDS#2-101408					
/MS/ Udagawa, N. et al., "Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but no macrophage colony-stimulating factors", Bone, 25: 517-523 (1999)									
000000000000000000000000000000000000000	12	Watanabe et al., "Interlukin-4 as a potent inhibitor of bone resorption", Biochemical and Biophysical Research Communications, 172(3): 1035-141 (1990)							
000000000000000000000000000000000000000	13	Willard, D. et al., "Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain", Protein Expr. Purif., 20: 48-57 (2000)							
***************************************	14	Wong et al., J. Biol. Chem. "The TRAF Family of Signal Transducers Mediates NF-кВ Activation by the TRANCE Receptor", 273(43): 28355-28359 (1998)							
000000000000000000000000000000000000000	15	Yoneda et al., "Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer", Cancer Research, 55: 1989-1993 (1995)							
/MS/	16	Zhang et al., "Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways", J. Biol. Chem., 276(1): 563-568 (January 5, 2001)							
If you w	ish to a	dd additional non-patent literatu	re document citation infor	matior	n please click the Add b	outton Add			
EXAMINER SIGNATURE									
Examine	er Sign	ature /Michael Szperka/			Date Considered	01/05/2009			
		nitial if reference considered, who conformance and not considere							

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.